Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 9102 results

  1. Advanced breast cancer: diagnosis and management (Partial update)

    In development Reference number: GID-NG10430 Expected publication date: TBC

    NICE guideline
    In development

  2. Pimicotinib for treating tenosynovial giant cell tumours when systemic treatment is needed [ID6647]

    In development Reference number: GID-TA11859 Expected publication date: TBC

    Technology appraisal guidance
    In development

  3. Bepirovirsen with nucleoside or nucleotide analogues for treating chronic hepatitis B [ID6608]

    In development Reference number: GID-TA11803 Expected publication date:  10 March 2027

    Technology appraisal guidance
    In development

  4. Pulsed Field Ablation for Atrial Fibrillation

    Awaiting development Reference number: GID-HTG10866 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  5. Brentuximab vedotin in combination for untreated advanced classical Hodgkin lymphoma [ID6437]

    In development Reference number: GID-TA11516 Expected publication date:  06 May 2027

    Technology appraisal guidance
    In development

  6. Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments (review of TA677) [ID6325]

    In development Reference number: GID-TA11545 Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Baloxavir marboxil granules for treating and preventing influenza in people 3 weeks and over [TSID12432]

    Awaiting development Reference number: GID-TA12479 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]

    In development Reference number: GID-TA11995 Expected publication date:  08 October 2026

    Technology appraisal guidance
    In development

  9. Efgartigimod for treating chronic inflammatory demyelinating polyneuropathy [ID6409]

    In development Reference number: GID-TA11508 Expected publication date:  18 November 2026

    Technology appraisal guidance
    In development

  10. Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304]

    In development Reference number: GID-TA11100 Expected publication date:  13 May 2027

    Technology appraisal guidance
    In development

  11. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    In development Reference number: GID-TA11956 Expected publication date:  28 January 2027

    Technology appraisal guidance
    In development

  12. Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399]

    Awaiting development Reference number: GID-TA11499 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Secukinumab for treating relapsed polymyalgia rheumatica ID6599: consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

    We are listening to your views on this Technology appraisal guidance. Comments close 22 July 2026.

    Technology appraisal guidance
    In consultation

  14. Sirolimus gel for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older (review of TA972) [ID6440]

    In development Reference number: GID-TA11554 Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Alcohol Use Disorders (update)

    In development Reference number: GID-NG10445 Expected publication date: TBC

    NICE guideline
    In development